Pathological significance of abnormal recepteur d’origine nantais and programmed death ligand 1 expression in colorectal cancer

Table 3 Comparison of RON (tumor cells) and PD-L1 (tumor-infiltrating mononuclear cells) expression and clinicopathological characteristics of patients with colorectal cancer in the FAHZUSM cohort, n (%)

Characteristic	Cases	RON and PD-L1 (TIMCs) expression in the tumor microenvironment
		RON low/PD-L1 low	RON high/PD-L1 low	RON low/PD-L1 high	RON high/PD-L1 high	P value
Number of cases	338	177	70	65	26
Age (mean ± SD)	61.24 ± 12.555	60.37 ± 12.299	62.40 ± 12.518	61.03 ± 13.286	64.58 ± 12.436	0.348
Sex
Man	197 (58.3)	108 (61)	35 (50.0)	40 (61.5)	14 (52.8)	0.368
Women	141 (41.7)	68 (39)	35 (50.0)	25 (38.5)	12 (46.2)
Principal diagnosis
Rectum	200 (59.2)	116 (65.5)	37 (52.9)	28 (43.1)	19 (73.1)	0.004
Colon	138 (40.8)	61 (34.5)	33 (47.1)	37 (56.9)	7 (26.9)
Pathological grade
Well/moderate	8 (2.4)	3 (1.7)	2 (2.9)	3 (4.6)	0 (0)	0.492
Poor	306 (90.5)	158 (89.3)	66 (94.3)	58 (89.2)	24 (92.3)
Unknown	24 (7.1)	16 (9.0)	2 (2.9)	4 (6.2)	2 (7.7)
T stage
Tis-T2	96 (28.4)	64 (36.2)	9 (12.9)	16 (2.6)	7 (26.9)	0.002
T3	155 (45.9)	82 (46.3)	36 (51.4)	28 (43.1)	9 (34.6)
T4	87 (25.7)	31 (17.5)	25 (35.7)	21 (32.3)	10 (38.5)
N stage
N0	226 (66.9)	125 (70.6)	39 (55.7)	47 (72.3)	15 (57.7)	0.075
N (1-2)	112 (33.1)	52 (29.4)	31 (44.3)	18 (27.7)	11 (42.3)
M stage
M0	326 (96.4)	173 (97.7)	68 (97.1)	61 (93.8)	24 (92.3)	0.235
M1	12 (3.6)	4 (2.3)	2 (2.9)	4 (2.3)	2 (7.7)
Stage
0-II	221 (65.4)	123 (69.5)	39 (55.7)	45 (69.2)	14 (53.8)	0.104
III-IV	117 (34.6)	54 (30.5)	31 (33.3)	20 (30.8)	12 (46.2)
Histological type
Adenocarcinoma	287 (84.9)	152 (85.9)	62 (88.6)	60 (92.3)	13 (50)	< 0.001
Mucinous/SRCC	40 (11.8)	21 (11.9)	7 (10.0)	3 (4.6)	9 (34.6)
Other	11 (3.3)	4 (2.3)	1 (1.4)	2 (3.1)	4 (15.4)
Treatment
Yes	298 (88.2)	83 (46.9)	22 (31.4)	30 (46.2)	24 (92.3)	< 0.001
No	32 (9.5)	74 (41.8)	38 (54.3)	25 (38.5)	1 (3.8)
Unknown	8 (2.4)	20 (11.3)	10 (14.3)	10 (15.4)	1 (3.8)

Bold entries indicate statistical significance (P < 0.05). RON: Recepteur d’origine nantais; PD-L1: Programmed death ligand 1; TCs: Tumor cells; TIMCs: Tumor-infiltrating mononuclear cells; FAHZUSM: The First Affiliated Hospital, Zhejiang University School of Medicine.